Efg Asset Management (North America) Corp. Karuna Therapeutics, Inc. Transaction History

Efg Asset Management (North America) Corp.

$566 Million
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$161.01 - $317.85 $258,421 - $510,149	1,605 Added 27.16%	7,514 $2.38 Million
Q3 2023 Nov 02, 2023	SELL	$164.66 - $218.08 $93,032 - $123,215	-565 Reduced 8.73%	5,909 $999,000
Q2 2023 Jul 28, 2023	SELL	$176.32 - $240.22 $67,706 - $92,244	-384 Reduced 5.6%	6,474 $1.4 Million
Q1 2023 Apr 27, 2023	BUY	$161.33 - $204.36 $159,232 - $201,703	987 Added 16.81%	6,858 $1.25 Million
Q4 2022 Feb 03, 2023	SELL	$191.53 - $236.82 $37,731 - $46,653	-197 Reduced 3.25%	5,871 $1.15 Million
Q3 2022 Oct 28, 2022	BUY	$123.79 - $277.42 $751,157 - $1.68 Million	6,068 New	6,068 $1.36 Million

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.

Account